재조합 단백질 치료제 CDMO 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Recombinant Protein Therapeutics CDMO Market size is expected to reach USD 103.65 Billion in 2034 from USD 31.35 Billion (2025) growing at a CAGR of 14.21% during 2026-2034.

The Global Recombinant Protein Therapeutics CDMO Market is experiencing strong growth driven by increasing demand for biologics and biosimilars. Pharmaceutical companies are outsourcing manufacturing to contract development and manufacturing organizations (CDMOs) to reduce costs and accelerate time-to-market. Rising prevalence of chronic diseases has significantly increased demand for protein-based therapeutics.

Major growth drivers include advancements in bioprocessing technologies, expanding biotechnology sector, and increasing regulatory approvals for biologic drugs. The growing focus on monoclonal antibodies and targeted therapies has strengthened market demand. Additionally, CDMOs offer scalable production capabilities, attracting both emerging biotech firms and established pharmaceutical companies.

Looking forward, the market is expected to benefit from innovations in cell line development and continuous manufacturing processes. Expansion of biologics pipelines and increasing investments in biopharmaceutical research will further drive growth. Emerging markets are likely to play a crucial role in expanding manufacturing capacities, ensuring sustained long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Growth Hormones
• Interferons
• Vaccines
• Immunostimulating Agents
• Others

By Source

• Mammalian Systems
• Microbial Systems
• Others

By Indication

• Oncology
• Infectious Diseases
• Immunological Disorders
• Metabolic Disorders
• Haematological Disorders
• Others

By Service Type

• Contract Manufacturing
• Contract Development

By End Use

• Pharmaceutical Companies
• Biotech Companies
• Others

COMPANIES PROFILED

• RichterHelm BioLogics, Lonza, Catalent Inc, Fujifilm Diosynth Biotechnologies, WuXi Biologics, Curia Global Inc, Batavia Biosciences BV, HALIX BV, Biovian, Enzene Biosciences Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Growth Hormones Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Interferons Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Immunostimulating Agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY SOURCE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Source
• 5.2. Mammalian Systems Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Microbial Systems Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Immunological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Metabolic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Haematological Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Service Type
• 7.2. Contract Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Contract Development Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY END USE 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End Use
• 8.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Biotech Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Type
  • 9.2.2 By Source
  • 9.2.3 By Indication
  • 9.2.4 By Service Type
  • 9.2.5 By End Use
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Type
  • 9.3.2 By Source
  • 9.3.3 By Indication
  • 9.3.4 By Service Type
  • 9.3.5 By End Use
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Type
  • 9.4.2 By Source
  • 9.4.3 By Indication
  • 9.4.4 By Service Type
  • 9.4.5 By End Use
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Type
  • 9.5.2 By Source
  • 9.5.3 By Indication
  • 9.5.4 By Service Type
  • 9.5.5 By End Use
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Type
  • 9.6.2 By Source
  • 9.6.3 By Indication
  • 9.6.4 By Service Type
  • 9.6.5 By End Use
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 Richter-Helm BioLogics
  • 11.2.2 Lonza
  • 11.2.3 Catalent Inc
  • 11.2.4 Fujifilm Diosynth Biotechnologies
  • 11.2.5 WuXi Biologics
  • 11.2.6 Curia Global Inc
  • 11.2.7 Batavia Biosciences B.V
  • 11.2.8 HALIX B.V
  • 11.2.9 Biovian
  • 11.2.10 Enzene Biosciences Ltd